Immunodeficiency Secondary to Malignancies and Biologics
Source : https://link.springer.com/chapter/10.1007/978-3-030-57157-3_21
S. Shahzad Mustafa There are many causes for secondary immunodeficiency (SID), which commonly presents with increased risk of infections. B-cell malignancies (multiple myeloma, chronic lymphocytic leukemia, non-Hodgkin's lymphoma) and chemotherapeutics...
Measurable residual disease in multiple myeloma and light chain amyloidosis: more than meets the eye
Source : https://doi.org/10.1080/10428194.2021.1873320
Abstract The emergence of highly effective multiple myeloma (MM) treatments may bring cure within reach and highlights the need for highly sensitive measurable residual disease (MRD) techniques to replace conventional...
Identification of key genes in relapsed multiple myeloma by weighted gene co-expression network analysis
Source : https://www.researchsquare.com/article/rs-153300/v1
Background Multiple myeloma is a hematologic disorder of abnormal plasma cell proliferation. Although there are some agents with different mechanisms in the clinic, the treatment of multiple myeloma is still...
Immunotherapeutic strategies targeting B cell maturation antigen in multiple myeloma
Source : https://mmrjournal.biomedcentral.com/articles/10.1186/s40779-021-00302-x
Multiple myeloma (MM) is the second most common hematologic malignancy, and is characterized by the clonal expansion of malignant plasma cells. Despite the recent improvement in patient outcome due to...
A Phase I Study of a Novel Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed/Refractory Multiple Myeloma | Request PDF
Request PDF | A Phase I Study of a Novel Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed/Refractory Multiple Myeloma | B cell maturation antigen- (BCMA) specific chimeric antigen...